Navigation Links
DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
Date:5/16/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., May 16, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar Pharma") is pleased to provide the following update from President & CEO, Mr. Jeffrey Bacha :

During the past quarter, we continued to advance our lead product candidate VAL-083 in an ongoing brain cancer clinical trial.  Our current trial is a dose-escalating study designed to evaluate the safety and efficacy of VAL-083 as a potential treatment for glioblastoma multiforme (GBM) and metastatic brain cancer for patients who have failed or are otherwise ineligible for currently approved treatments. 

We recently presented encouraging data at the American Association of Cancer Research (AACR) 2013 annual meeting showing that VAL-083, at doses tested to date:

  • Is safe and well tolerated in patients who have failed other available therapies;
  • Demonstrated a dose response, as expected, based on observations reported in the historical literature; and
  • Demonstrated clinical activity: an overall response rate of 33.3% was observed, where tumor growth had stabilized or regressed, in patients that had failed other therapies.

Based on these observations, we are focused on completing the dose escalation portion of the clinical trial with the goal of positioning VAL-083 for advancement into registration directed clinical trials.  We anticipate presenting additional data at upcoming scientific meetings during 2013.

In addition to our clinical development activities in the United States, we have obtained exclusive commercial rights to VAL-083 in China, where the drug is approved as a chemotherapy for the treatment or chronic myelogenous leukemia (CML) and lung cancer.  Our strateg
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... STUTTGART , Alemania, December 17, 2014 ... del año anterior, con un alto nivel de gasto ... pasado año fiscal 2013/14 (finalizado el 30 de septiembre ... por ciento a 4.287 millones de euros (año anterior: ... de la moneda desfavorables. Las ganancias (EBIT) crecieron un ...
(Date:12/17/2014)...  Northstar Global Business Services, Inc. (OTCPink:MDIN) today ... made their final decision and has determined to ... effective December 15, 2014, and has resumed accepting ... book entry transfer services. All deposit restrictions have been ... fully "DTC Eligible", and has resumed electronic trading ...
(Date:12/17/2014)... , The new Dompé website ... concerning the biopharmaceutical Group,s national and international clinical research activities ... recently launched institutional website that is receiving accolades from all ... new chapter in the fascinating story of Drug Discovery   ... hub on the world of clinical research, ranging from information ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... The jury verdict in the case of State of ... Inc. has been upheld and requests for a new ... against the manufacturers of the drug Risperdal. Circuit Court ... through two written orders. One order denies the defendant,s ...
... TUSTIN, Calif., Dec. 21, 2011   Uptake Medical ® ... (TGA) approval for its InterVapor ™ System for ... emphysema.  InterVapor is the first non-surgical, endoscopic lung volume ... uses the body,s natural healing processes without leaving implants ...
Cached Medicine Technology:Record Breaking $327 Million Verdict Upheld in Janssen Case and Request for New Trial Denied 2Uptake Medical Announces TGA Approval of InterVapor for Patients With Severe Emphysema 2Uptake Medical Announces TGA Approval of InterVapor for Patients With Severe Emphysema 3
(Date:12/17/2014)... December 17, 2014 A group of 127 ... Longevity, today, in reaction to a recent statement by the ... brain training and derogated the efficacy of all brain exercises. ... with the parts of the center’s statement critical of brain ... center had also overstated its case, in a document it ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Project Veritas ... recently brought videos of MIT economist and Obamacare architect ... author James O’Keefe conducted the interview, which is being ... that there was intentional mislabeling in the Affordable Care ... the bill: A two-hundred-and-fifty billion dollar per year tax ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... phenomenon is when an illness that originated in animals jumps ... -- is not uncommon and keeps researchers on their toes ... make inroads into the human population. A new report ... in this case were guinea pigs. More specifically, they were ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Poor students get more fruits and ... study finds. But, the opposite is true for students ... and vegetables at school may give a healthy boost to ... matter what the family income level, students all ate a ... found. The study was published recently in the journal ...
Breaking Medicine News(10 mins):Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Poor Students Eat Healthier Foods at School, Study Finds 2
... 8 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... of medical devices worldwide announced today it filed ... on Form 20-F that included,audited financial statements for ... of Mindray,s Annual Report on Form 20-F is ...
... Challenge Grant Demonstrate Effectiveness of Public-Private Partnerships to ... LAKES, N.J., May 8 Two days before ... leading global medical technology company, announced its continued ... campaign to vaccinate mothers and children in developing ...
... Software, part of the Elekta Group, has been selected ... during the 2009 American Society of Clinical Oncology,s (ASCO) ... Orange County Convention Center, in Orlando, Florida. Chosen according ... the third consecutive year Impac Software ...
... Reached American Diabetes Association,s Recommended Average Blood Sugar ... Novo Nordisk today announced results from ... [rDNA origin] injection), taken once-daily, substantially lowered average ... more active role in their treatment by adjusting ...
... Va., May 8, 2009 AMERIGROUP Corporation (NYSE: ... in the Deutsche Bank 34th Annual Healthcare Conference on May ... begins Monday, May 18 at 2:25pm Eastern Time, can be ... on the investors, page. A replay will be available for ...
... advances likely behind drop in bypass procedures , , FRIDAY, ... advances in heart surgery and improved heart disease prevention ... number of patients in the United States having coronary ... Rates of bypass surgery steadily increased between the late ...
Cached Medicine News:Health News:Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission 2Health News:BD Extends Decade-Long Support for UNICEF's Campaign to Eliminate Maternal and Neonatal Tetanus 2Health News:BD Extends Decade-Long Support for UNICEF's Campaign to Eliminate Maternal and Neonatal Tetanus 3Health News:BD Extends Decade-Long Support for UNICEF's Campaign to Eliminate Maternal and Neonatal Tetanus 4Health News:Impac Software Selected to Present at the Electronic Health Records Lab During 2009 ASCO Annual Meeting 2Health News:Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study 2Health News:Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study 3Health News:Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study 4Health News:Fewer Heart Surgeries Needed as Technology Improves 2
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
... provides quick, convenient, repetitive dispensing for ... have a polyethylene plunger and a ... use with most reagents. Application: ... separate volumes can be selected for ...
The True Non-Compliant Balloon....
Inquire...
Medicine Products: